nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.12.2012

Crosstalk Between the Renin–Angiotensin System and the Advance Glycation End Product Axis in the Heart: Role of the Cardiac Fibroblast

verfasst von: Katrina Go Yamazaki, Eileen Gonzalez, Alexander C. Zambon

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Cardiac fibroblasts (CFs) are involved in maintaining extracellular matrix (ECM) homeostasis in the heart. CFs mediate responses to hormonal and mechanical stimuli and relay these to other local cell types through release of autocrine and/or paracrine factors. CFs also play important roles in the setting of injury, i.e., myocardial infarction, where ECM production is key to efficient scarring. However, conditions exist in which excess production of ECM by CFs can lead to cardiac fibrosis. Two important pathways known to be involved in development of cardiac fibrosis are renin–angiotensin system (RAS) and advanced glycation end products (AGE) receptor (RAGE) signaling cascades. This report summarizes actions of these two pathways on function of CFs. Because cardiac fibrosis is an important component of diabetic cardiomyopathy, we include new data that suggests a possible crosstalk between the RAS and AGE/RAGE pathway in order to activate CFs in diabetes.

Carey, R. M., & Siragy, H. M. (2003). Newly recognized components of the renin–angiotensin system: Potential roles in cardiovascular and renal regulation. Endocrine Reviews, 24(3), 261–271.PubMedCrossRef

Unger, T., Paulis, L., & Sica, D. A. Therapeutic perspectives in hypertension: Novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches. European Heart Journal, 32(22), 2739–2747. doi:10.1093/eurheartj/ehr253.

Paul, M., Poyan Mehr, A., & Kreutz, R. (2006). Physiology of local renin–angiotensin systems. Physiological Reviews, 86(3), 747–803. doi:10.1152/physrev.00036.2005.PubMedCrossRef

Ma, T. K., Kam, K. K., Yan, B. P., & Lam, Y. Y. Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: Current status. British Journal of Pharmacology, 160(6), 1273–1292. doi:10.1111/j.1476-5381.2010.00750.x.

Dostal, D. E., & Baker, K. M. (1999). The cardiac renin–angiotensin system: Conceptual, or a regulator of cardiac function? Circulation Research, 85(7), 643–650.PubMedCrossRef

Gray, M. O., Long, C. S., Kalinyak, J. E., Li, H. T., & Karliner, J. S. (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovascular Research, 40(2), 352–363.PubMedCrossRef

Buhler, F. R., Bolli, P., Kiowski, W., Erne, P., Hulthen, U. L., & Block, L. H. (1984). Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. American Journal of Medicine, 77(2A), 36–42.PubMed

Weiss, D., Sorescu, D., & Taylor, W. R. (2001). Angiotensin II and atherosclerosis. The American Journal of Cardiology, 87(8A), 25C–32C.PubMedCrossRef

Weiss, D., Kools, J. J., & Taylor, W. R. (2001). Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation, 103(3), 448–454.PubMedCrossRef

10.

Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005). The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and Toxicology, 45, 657–687. doi:10.1146/annurev.pharmtox.45.120403.095802.PubMedCrossRef

11.

Iwata, M., Cowling, R. T., Yeo, S. J., & Greenberg, B. Targeting the ACE2–Ang-(1–7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. Journal of Molecular and Cellular Cardiology, 51(4), 542–547. doi:10.1016/j.yjmcc.2010.12.003.

12.

Singh, V. P., Baker, K. M., & Kumar, R. (2008). Activation of the intracellular renin–angiotensin system in cardiac fibroblasts by high glucose: Role in extracellular matrix production. American Journal of Physiology. Heart and Circulatory Physiology, 294(4), H1675–H1684. doi:10.1152/ajpheart.91493.2007.PubMedCrossRef

13.

Kim, N. N., Villarreal, F. J., Printz, M. P., Lee, A. A., & Dillmann, W. H. (1995). Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. American Journal of Physiology, 269(3 Pt 1), E426–E437.PubMed

14.

Asbun, J., & Villarreal, F. J. (2006). The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. Journal of the American College of Cardiology, 47(4), 693–700. doi:10.1016/j.jacc.2005.09.050.PubMedCrossRef

15.

Vlassara, H., & Palace, M. R. (2002). Diabetes and advanced glycation endproducts. Journal of Internal Medicine, 251(2), 87–101.PubMedCrossRef

16.

Asbun, J., Manso, A. M., & Villarreal, F. J. (2005). Profibrotic influence of high glucose concentration on cardiac fibroblast functions: Effects of losartan and vitamin E. American Journal of Physiology. Heart and Circulatory Physiology, 288(1), H227–H234. doi:10.1152/ajpheart.00340.2004.PubMedCrossRef

17.

Aronson, D. (2003). Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension, 21(1), 3–12. doi:10.1097/01.hjh.0000042892.24999.92.PubMedCrossRef

18.

Cooper, M. E. (2004). Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. American Journal of Hypertension, 17(12 Pt 2), 31S–38S. doi:10.1016/j.amjhyper.2004.08.021.PubMedCrossRef

19.

Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch. (2006). Diabetes and advanced glycoxidation end products. Diabetes Care, 29(6), 1420–1432. doi:10.2337/dc05-2096.PubMedCrossRef

20.

Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006). Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation, 114(6), 597–605. doi:10.1161/CIRCULATIONAHA.106.621854.PubMedCrossRef

21.

Stern, D. M., Yan, S. D., Yan, S. F., & Schmidt, A. M. (2002). Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Research Reviews, 1(1), 1–15.PubMedCrossRef

22.

Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005). Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine (Berlin), 83(11), 876–886. doi:10.1007/s00109-005-0688-7.CrossRef

23.

Steckelings, U. M., Rompe, F., Kaschina, E., & Unger, T. (2009). The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundamental and Clinical Pharmacology, 23(6), 693–703. doi:10.1111/j.1472-8206.2009.00780.x.PubMedCrossRef

24.

Huang, J. S., Guh, J. Y., Hung, W. C., Yang, M. L., Lai, Y. H., Chen, H. C., & Chuang, L. Y. (1999). Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. The Biochemical Journal, 342(Pt 1), 231–238.PubMedCrossRef

25.

Souders, C. A., Bowers, S. L., & Baudino, T. A. (2009). Cardiac fibroblast: The renaissance cell. Circulation Research, 105(12), 1164–1176. doi:10.1161/CIRCRESAHA.109.209809.PubMedCrossRef

26.

Liu, X., Ostrom, R. S., & Insel, P. A. (2004). cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. American Journal of Physiology. Cell Physiology, 286(5), C1089–C1099. doi:10.1152/ajpcell.00461.2003.PubMedCrossRef

27.

Madani, S., De Girolamo, S., Munoz, D. M., Li, R. K., & Sweeney, G. (2006). Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovascular Research, 69(3), 716–725. doi:10.1016/j.cardiores.2005.11.022.PubMedCrossRef

28.

Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V., Kehrl, J. H., et al. (1986). Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 83(12), 4167–4171.PubMedCrossRef

29.

Iwata, M., Cowling, R. T., Gurantz, D., Moore, C., Zhang, S., Yuan, J. X., & Greenberg, B. H. (2005). Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. American Journal of Physiology. Heart and Circulatory Physiology, 289(6), H2356–H2363. doi:10.1152/ajpheart.00317.2005.PubMedCrossRef

30.

Zahradka, P., Werner, J. P., Buhay, S., Litchie, B., Helwer, G., & Thomas, S. (2002). NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. Journal of Molecular and Cellular Cardiology, 34(12), 1609–1621.PubMedCrossRef

31.

Meszaros, J. G., Gonzalez, A. M., Endo-Mochizuki, Y., Villegas, S., Villarreal, F., & Brunton, L. L. (2000). Identification of G protein-coupled signaling pathways in cardiac fibroblasts: Cross talk between G(q) and G(s). American Journal of Physiology. Cell Physiology, 278(1), C154–C162.PubMed

32.

Kumar, U. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine, 40(2), 168–180. doi:10.1007/s12020-011-9524-8.

33.

Olivares-Reyes, J. A., Shah, B. H., Hernandez-Aranda, J., Garcia-Caballero, A., Farshori, M. P., Garcia-Sainz, J. A., & Catt, K. J. (2005). Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Molecular Pharmacology, 68(2), 356–364. doi:10.1124/mol.104.010637.PubMed

34.

Kamioka, M., Ishibashi, T., Sugimoto, K., Uekita, H., Nagai, R., Sakamoto N, et al. Blockade of renin–angiotensin system attenuates advanced glycation end products-mediated signaling pathways. Journal of Atherosclerosis and Thrombosis, 17(6), 590–600.

35.

Hattori, Y., Suzuki, M., Hattori, S., & Kasai, K. (2002). Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension, 39(1), 22–28.PubMedCrossRef

36.

Forbes, J. M., Thorpe, S. R., Thallas-Bonke, V., Pete, J., Thomas, M. C., Deemer, E. R., Bassal, S., El-Osta, A., Long, D. M., Panagiotopoulos, S., Jerums, G., Osicka, T. M., & Cooper, M. E. (2005). Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. Journal of the American Society of Nephrology, 16(8), 2363–2372. doi:10.1681/ASN.2005010062.PubMedCrossRef

37.

Nakamura, K., Yamagishi, S., Nakamura, Y., Takenaka, K., Matsui, T., Jinnouchi, Y., & Imaizumi, T. (2005). Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvascular Research, 70(3), 137–141. doi:10.1016/j.mvr.2005.10.002.PubMedCrossRef

38.

Tang, M., Zhong, M., Shang, Y., Lin, H., Deng, J., Jiang, H., Lu, H., Zhang, Y., & Zhang, W. (2008). Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cellular and Molecular Life Sciences, 65(18), 2924–2932. doi:10.1007/s00018-008-8255-3.PubMedCrossRef

39.

Huang, J. S., Guh, J. Y., Chen, H. C., Hung, W. C., Lai, Y. H., & Chuang, L. Y. (2001). Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cellular Biochemistry, 81(1), 102–113. doi:10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y.PubMedCrossRef

40.

Forbes, J. M., Thomas, M. C., Thorpe, S. R., Alderson, N. L., & Cooper, M. E. (2004). The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney International. Supplement, 92, S105–S107. doi:10.1111/j.1523-1755.2004.09225.x.PubMedCrossRef

41.

Ban, C. R., & Twigg, S. M. (2008). Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vascular Health and Risk Management, 4(3), 575–596.PubMed

42.

Daoud, S., Schinzel, R., Neumann, A., Loske, C., Fraccarollo, D., Diez, C., & Simm, A. (2001). Advanced glycation endproducts: Activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Molecular Medicine, 7(8), 543–551.PubMed

43.

Henry, R. M., Paulus, W. J., Kamp, O., Kostense, P. J., Spijkerman, A. M., Dekker, J. M., Nijpels, G., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. (2008). Deteriorating glucose tolerance status is associated with left ventricular dysfunction—the Hoorn Study. The Netherlands Journal of Medicine, 66(3), 110–117.PubMed

44.

Mizushige, K., Yao, L., Noma, T., Kiyomoto, H., Yu, Y., Hosomi, N., Ohmori, K., & Matsuo, H. (2000). Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation, 101(8), 899–907.PubMedCrossRef

45.

Reddy, V. S., Harskamp, R. E., van Ginkel, M. W., Calhoon, J., Baisden, C. E., Kim, I. S., Valente, A. J., & Chandrasekar, B. (2008). Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. Journal of Cellular Physiology, 215(3), 697–707. doi:10.1002/jcp.21348.PubMedCrossRef

46.

Wolf, G., Wenzel, U., Burns, K. D., Harris, R. C., Stahl, R. A., & Thaiss, F. (2002). Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney International, 61(6), 1986–1995. doi:10.1046/j.1523-1755.2002.00365.x.PubMedCrossRef

47.

Lee, C. I., Guh, J. Y., Chen, H. C., Hung, W. C., Yang, Y. L., & Chuang, L. Y. (2005). Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells. Journal of Cellular Biochemistry, 95(2), 281–292. doi:10.1002/jcb.20380.PubMedCrossRef

48.

Bierhaus, A., Chevion, S., Chevion, M., Hofmann, M., Quehenberger, P., Illmer, T., Luther, T., Berentshtein, E., Tritschler, H., Muller, M., Wahl, P., Ziegler, R., & Nawroth, P. P. (1997). Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 46(9), 1481–1490.PubMedCrossRef

Titel: Crosstalk Between the Renin–Angiotensin System and the Advance Glycation End Product Axis in the Heart: Role of the Cardiac Fibroblast
verfasst von: Katrina Go Yamazaki
Eileen Gonzalez
Alexander C. Zambon
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 6/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-012-9405-4

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Crosstalk Between the Renin–Angiotensin System and the Advance Glycation End Product Axis in the Heart: Role of the Cardiac Fibroblast

Abstract

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Origin of Developmental Precursors Dictates the Pathophysiologic Role of Cardiac Fibroblasts

Cardiac Fibroblasts and Cellular Cross Talk in Heart Failure

The Dynamic Role of Cardiac Fibroblasts in Development and Disease

Cardiac Intercellular Communication: Are Myocytes and Fibroblasts Fair-Weather Friends?

The Origin and Arrhythmogenic Potential of Fibroblasts in Cardiac Disease

The Actin–MRTF–SRF Gene Regulatory Axis and Myofibroblast Differentiation

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie